The Greenphage team is happy and proud to announce the completion of its latest funding round!
After successfully conducting the first anti-Escherichia coli treatments at an industrial site in late 2024, Greenphage is entering a new phase of development by securing a total funding of €1.9M from IRDI Capital Investissement, SOFILARO / CALEN, Sud Mer Invest (Banque Populaire du Sud, GO CAPITAL), and Environnement Massif Central.
These capital inputs support a comprehensive financing plan of around €4M to multiply treated sites starting this summer, commission France’s first large-scale bacteriophage production unit, and further develop R&D for new applications.
Special thanks to Frederic PLANCHE, Yanaële Payen, Lucie Ayala, Lucas Grillard, Patrice ROCH, Marie-Sophie Redon, Genevieve Blanc, Clémentine BREYSSE, Olivier Dalle, Romain Carrel, BIC de Montpellier, MedVallée Montpellier, Pauline A., French Tech Méditerranée, CleanTech Vallée, Leader Montpellier, Banque Populaire du Sud, Crédit Agricole du Languedoc for their invaluable support.
